Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grazoprevir/ruzasvir/uprifosbuvir - Merck & Co

Drug Profile

Grazoprevir/ruzasvir/uprifosbuvir - Merck & Co

Alternative Names: Grazoprevir/MK-3682/MK-8408; Grazoprevir/MK-3682/ruzasvir; Grazoprevir/ruzasvir/MK-3682; Grazoprevir/uprifosbuvir/ruzasvir; MK-3682/grazoprevir/ruzasvir; MK-3682/ruzasvir/grazoprevir; MK-3682B; MK-5172/MK-3682/MK-8408; MK3; Ruzasvir/grazoprevir/MK-3682; Ruzasvir/grazoprevir/uprifosbuvir; Ruzasvir/MK-3682/grazoprevir; Ruzasvir/uprifosbuvir/grazoprevir; Uprifosbuvir/grazoprevir/ruzasvir; Uprifosbuvir/ruzasvir/grazoprevir

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antivirals; Benzoxazines; Cyclopropanes; Imidazoles; Indoles; Macrocyclic compounds; Pyrimidines; Pyrrolidines; Quinoxalines; Small molecules; Thiazoles; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Dec 2017 Chemical structure information added
  • 29 Sep 2017 Discontinued - Phase-III for Hepatitis C in Denmark, Lithuania (PO)
  • 29 Sep 2017 Merck terminates a phase II trial in Hepatitis C based on a review of phase II efficacy data in Belgium (PO) (EudraCT2016-000620-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top